| Literature DB >> 32489393 |
Krzysztof Durkalec-Michalski1,2, Paulina M Nowaczyk1, Jacek Adrian3, Joanna Kamińska4, Tomasz Podgórski4.
Abstract
BACKGROUND: The aims of this study were to verify the effect of progressive-chronic and acute sodium bicarbonate (SB) supplementation on the anaerobic capacity, blood acid-base balance, and discipline-specific performance in team sports disciplines.Entities:
Keywords: Acid-base balance; Alkalizing agent; Buffering; Ergogenic support; Exercise performance; Sports nutrition
Year: 2020 PMID: 32489393 PMCID: PMC7245907 DOI: 10.1186/s12986-020-00457-9
Source DB: PubMed Journal: Nutr Metab (Lond) ISSN: 1743-7075 Impact factor: 4.169
Fig. 1Flow diagram of the study design. Abbreviations: T1 − 1st series of test procedures, T2 − 2nd series of test procedures, T3 − 3rd series of test procedures, T4 − 4th series of test procedures, PLA − placebo, SB − sodium bicarbonate
Baseline characteristics and typical structure of training loads in tested athletes during chronic and acute supplementation period
| Field hockey players | |||
|---|---|---|---|
| Chronic-group | Acute-group | ||
| n | 12 | 12 | – |
| Age (years) | 24.3 ± 5.6 | 22.2 ± 2.6 | 0.261 |
| Body mass (kg) | 75.0 ± 8.3 | 82.2 ± 14.1 | 0.142 |
| Body height (cm) | 176 ± 5 | 183 ± 8 | 0.022 |
| Body Mass Index (kg/m2) | 24.2 ± 2.2 | 24.4 ± 2.3 | 0.822 |
| Fat mass (%) | 12.6 ± 3.2 | 12.7 ± 4.2 | 0.942 |
| Fat-free mass (%) | 87.4 ± 3.2 | 87.3 ± 4.2 | 0.942 |
| Peak power (W) | 733 ± 103 | 792 ± 153 | 0.272 |
| Mean power (W) | 577 ± 73 | 627 ± 107 | 0.202 |
| Time in specific performance test (s) | 923 ± 42 | 939 ± 26 | 0.191 |
| Training sessions per week (no.) | 4.7 ± 0.5 | 4.6 ± 0.7 | 0.931 |
| Competitions (no.) | 1 ± 0 | 1 ± 0 | – |
| Training time | |||
| total (hours) | 8.2 ± 0.9 | 7.8 ± 1.1 | 0.041 |
| per one training session (hours) | 1.8 ± 0.0 | 1.7 ± 0.0 | 0.021 |
1 Data analyzed by Mann−Whitney U test. 2 Data analyzed by t-test for independent variables
Results of Wingate anaerobic test before (WAnT_1) and after (WAnT_2) hockey-specific performance test – chronic supplementation strategy
| SB-PRE | SB-POST | PLA-PRE | PLA-POST | ||||
|---|---|---|---|---|---|---|---|
| Work effort (W) | WAnT _1 | 232 ± 19 | 243 ± 16 | 0.0051 | 234 ± 14 | 241 ± 14 | 0.0312 |
| 2.821 | 6.2572 | ||||||
| 0.821 | 0.3852 | ||||||
| WAnT _2 | 225 ± 23 | 228 ± 19 | 0.3652 | 227 ± 14 | 238 ± 17 | 0.1042 | |
| 0.8982 | 3.2052 | ||||||
| 0.0822 | 0.2432 | ||||||
| Mean power (W) | WAnT _1 | 575 ± 71 | 602 ± 67 | 0.0052 | 585 ± 73 | 602 ± 74 | 0.2642 |
| 12.502 | 1.3972 | ||||||
| 0.5562 | 0.1232 | ||||||
| WAnT _2 | 560 ± 90 | 567 ± 77 | 0.3822 | 569 ± 72 | 595 ± 74 | 0.3932 | |
| 0.8372 | 0.7962 | ||||||
| 0.0772 | 0.0742 | ||||||
| Peak power (W) | WAnT _1 | 749 ± 94 | 777 ± 96 | 0.0022 | 753 ± 105 | 784 ± 104 | 0.2542 |
| 17.3062 | 1.4642 | ||||||
| 0.6342 | 0.1282 | ||||||
| WAnT _2 | 714 ± 109 | 738 ± 117 | 0.1821 | 723 ± 89 | 762 ± 105 | 0.2222 | |
| 1.3341 | 1.6992 | ||||||
| 0.381 | 0.1452 | ||||||
| Time to PP (s) | WAnT _1 | 6.10 ± 1.06 | 5.84 ± 0.94 | 0.2462 | 6.28 ± 0.87 | 5.98 ± 1.12 | 0.9422 |
| 1.5192 | 0.0062 | ||||||
| 0.1322 | 0.0012 | ||||||
| WAnT _2 | 5.77 ± 0.89 | 6.19 ± 1.16 | 0.7662 | 6.84 ± 2.46 | 5.88 ± 0.96 | 0.2322 | |
| 0.0932 | 1.6182 | ||||||
| 0.0092 | 0.1392 | ||||||
| Power carry threshold at 97%PP (W) | WAnT _1 | 727 ± 91 | 753 ± 93 | 0.0022 | 731 ± 102 | 761 ± 101 | 0.2442 |
| 17.1912 | 1.5322 | ||||||
| 0.6322 | 0.1332 | ||||||
| WAnT _2 | 693 ± 106 | 716 ± 114 | 0.1821 | 701 ± 86 | 740 ± 102 | 0.2282 | |
| 1.3341 | 1.6502 | ||||||
| 0.381 | 0.1422 | ||||||
| Average power over the PCT (W) | WAnT _1 | 739 ± 94 | 765 ± 95 | 0.0012 | 742 ± 104 | 774 ± 102 | 0.2302 |
| 21.4442 | 1.6322 | ||||||
| 0.6822 | 0.1402 | ||||||
| WAnT _2 | 704 ± 108 | 728 ± 116 | 0.1821 | 713 ± 87 | 752 ± 102 | 0.1972 | |
| 1.3341 | 1.9102 | ||||||
| 0.3801 | 0.1602 | ||||||
| HRmax (bpm) | WAnT _1 | 175 ± 8 | 172 ± 9 | 0.1602 | 173 ± 9 | 171 ± 9 | 0.1581 |
| 2.3002 | 1.4121 | ||||||
| 0.1872 | 0.4081 | ||||||
| WAnT _2 | 179 ± 6 | 177 ± 9 | 0.6832 | 177 ± 6 | 179 ± 8 | 0.1821 | |
| 0.1772 | 1.3341 | ||||||
| 0.0172 | 0.3851 |
1Data analyzed by Wilcoxon signed-rank test; effect size expressed as rank correlation coefficient (r). 2Data analyzed by two-way ANOVA with repeated measurements; effect size expressed as partial eta-squared (). Abbreviations: HRmax – maximal heart rate, PCT – power carry threshold at 97%PP, PLA-PRE – before placebo treatment, PLA-POST – after placebo treatment, PP – peak power, SB-PRE – before sodium bicarbonate supplementation, SB-POST – after sodium bicarbonate supplementation, WAnT_1 – the Wingate anaerobic test performed before hockey-specific performance test, WAnT_2 – the Wingate anaerobic test performed after hockey-specific performance test
Fig. 2Comparisons of “pre-post” absolute differences in WAnTs (“After” – “Before” treatment) between SB and PLA – chronic supplementation strategy. Abbreviations: PLA – placebo treatment, PP – peak power, SB – sodium bicarbonate supplementation, WAnT_1 – the Wingate anaerobic test performed before hockey-specific performance test, WAnT_2 – the Wingate anaerobic test performed after hockey-specific performance test
Results in hockey-specific performance test – chronic supplementation strategy
| SB-PRE | SB-POST | PLA-PRE | PLA-POST | Δ | Δ | ||||
|---|---|---|---|---|---|---|---|---|---|
| Time (s) | 919 ± 42 | 912 ± 27 | 0.0501 | 919 ± 33 | 920 ± 31 | 0.0882 | −6.5 ± 53.1 | 0.5 ± 32.6 | 0.6381 |
| 1.9561 | 3.5762 | 0.4711 | |||||||
| 0.5901 | 0.2632 | 0.1361 | |||||||
| HRmax (bpm) | 179 ± 5 | 179 ± 7 | 0.7561 | 179 ± 9 | 179 ± 7 | 0.2512 | −0.3 ± 3.9 | −0.7 ± 9.4 | 0.4241 |
| 0.3111 | 1.4852 | 0.8001 | |||||||
| 0.0941 | 0.1292 | 0.2411 | |||||||
| HRaverage (bpm) | 160 ± 6 | 159 ± 7 | 0.2661 | 159 ± 7 | 160 ± 7 | 0.6442 | −1.2 ± 4.7 | 1.0 ± 4.7 | 0.9632 |
| 1.1111 | 0.2272 | 0.0022 | |||||||
| 0.3351 | 0.0222 | 0.0002 |
1Data analyzed by Wilcoxon signed-rank test; effect size expressed as rank correlation coefficient (rc). 2Data analyzed by two-way ANOVA with repeated measurements; effect size expressed as partial eta-squared (). Abbreviations: HRaverage – average heart rate, HRmax – maximal heart rate, PLA-PRE – before placebo treatment, PLA-POST – after placebo treatment, SB-PRE – before sodium bicarbonate supplementation, SB-POST – after sodium bicarbonate supplementation
Results of Wingate anaerobic test before (WAnT_1) and after (WAnT_2) hockey-specific performance test – acute supplementation strategy
| BASE | SB | PLA | |||
|---|---|---|---|---|---|
| Work effort (W) | WAnT _1 | 229 ± 14 | 229 ± 14 | 226 ± 12 | 0.3971 |
| 0.8231 | |||||
| 0.0701 | |||||
| WAnT _2 | 215 ± 21 | 225 ± 18 | 217 ± 20 | 0.1061 | |
| 2.4921 | |||||
| 0.1851 | |||||
| Mean power (W) | WAnT _1 | 627 ± 107 | 636 ± 105 | 626 ± 104 | 0.3831 |
| 0.8771 | |||||
| 0.0741 | |||||
| WAnT _2 | 670 ± 71 | 700 ± 48 | 675 ± 66 | 0.1461 | |
| 2.1021 | |||||
| 0.1601 | |||||
| Peak power (W) | WAnT _1 | 792 ± 153 | 813 ± 146 | 783 ± 154 | 0.0661 |
| 3.0811 | |||||
| 0.2191 | |||||
| WAnT _2 | 849 ± 72 | 873 ± 75 | 857 ± 81 | 0.5161 | |
| 0.6821 | |||||
| 0.0581 | |||||
| Time to PP (s) | WAnT _1 | 6.19 ± 1.67 | 6.40 ± 1.78 | 6.30 ± 1.60 | 0.7601 |
| 0.2781 | |||||
| 0.0251 | |||||
| WAnT _2 | 8.00 ± 4.46 | 6.45 ± 2.40 | 7.04 ± 1.53 | 0.5582 | |
| 1.1672 | |||||
| 0.0492 | |||||
| Power carry threshold at 97%PP (W) | WAnT _1 | 769 ± 149 | 788 ± 142 | 760 ± 150 | 0.0651 |
| 3.1041 | |||||
| 0.2201 | |||||
| WAnT _2 | 823 ± 70 | 846 ± 73 | 831 ± 79 | 0.5161 | |
| 0.6811 | |||||
| 0.0581 | |||||
| Average power over the PCT (W) | WAnT _1 | 782 ± 151 | 801 ± 144 | 772 ± 152 | 0.0631 |
| 3.1371 | |||||
| 0.2221 | |||||
| WAnT _2 | 838 ± 71 | 860 ± 74 | 845 ± 80 | 0.5621 | |
| 0.5921 | |||||
| 0.0511 | |||||
| HRmax (bpm) | WAnT _1 | 170 ± 12 | 166 ± 10 | 168 ± 11 | 0.1522 |
| 3.7622 | |||||
| 0.1712 | |||||
| WAnT _2 | 175 ± 10 | 174 ± 7 | 174 ± 10 | 0.9471 | |
| 0.0541 | |||||
| 0.0061 |
1Data analyzed by one-way ANOVA with repeated measurements; effect size expressed as partial eta-squared (). 2Data analyzed by Friedman’s ANOVA and subsequent two-group comparisons by Wilcoxon signed-rank test; effect size expressed as Kendall’s Concordance Coefficient W. Abbreviations: BASE – baseline (no supplementation), HRmax – maximal heart rate, PCT – power carry threshold at 97%PP, PLA – after placebo treatment, PP – peak power, SB – after sodium bicarbonate supplementation, WAnT_1 – the Wingate anaerobic test performed before hockey-specific performance test, WAnT_2 – the Wingate anaerobic test performed after hockey-specific performance test
Results in hockey-specific performance test – acute supplementation strategy
| BASE | SB | PLA | ||
|---|---|---|---|---|
| Time (s) | 939 ± 26b | 914 ± 22a | 919 ± 20a | 0.006 |
| 6.480 | ||||
| 0.371 | ||||
| HRmax (bpm) | 179 ± 7 | 178 ± 7 | 178 ± 8 | 0.260 |
| 1.453 | ||||
| 0.139 | ||||
| HRaverage (bpm) | 163 ± 11b | 157 ± 7a | 160 ± 12a | 0.004 |
| 7.423 | ||||
| 0.452 |
ab – different letter inscriptions refer to statistical differences between BASE, PLA and SB. Abbreviations: BASE – baseline (no supplementation), HRaverage – average heart rate, HRmax – maximal heart rate, PLA – after placebo treatment, SB – after sodium bicarbonate supplementation
Blood acid-base balance markers – chronic supplementation strategy
| SB-PRE | SB-POST | PLA-PRE | PLA-POST | SB-POST vs. PLA-POST | ||||
|---|---|---|---|---|---|---|---|---|
| pH | EXERCISE_PRE | 7.41 ± 0.02 | 7.43 ± 0.02 | 0.1011 | 7.42 ± 0.02 | 7.43 ± 0.03 | 0.1831 | 0.7683 |
| −1.7921 | −1.4211 | 0.2983 | ||||||
| −0.6521 | − 0.4321 | 0.1223 | ||||||
| EXERCISE_POST | 7.18 ± 0.05 | 7.20 ± 0.05 | 0.3681 | 7.18 ± 0.05 | 7.18 ± 0.04 | 0.9211 | 0.3143 | |
| −0.9391 | −0.1021 | 1.0313 | ||||||
| −0.3901 | −0.0321 | 0.4213 | ||||||
| HCO3 | EXERCISE_PRE | 26.1 ± 0.8 | 27.2 ± 2.1 | 0.0681 | 26.3 ± 1.2 | 26.5 ± 1.6 | 0.9062 | 0.1664 |
| −2.0211 | 0.1182 | 47.5004 | ||||||
| −0.7191 | 0.0342 | 0.3404 | ||||||
| EXERCISE_POST | 13.1 ± 1.6 | 13.6 ± 1.5 | 0.5021 | 13.4 ± 1.6 | 13.2 ± 1.3 | 0.6701 | 0.4903 | |
| −0.6951 | 0.4381 | 0.7033 | ||||||
| −0.3061 | 0.1621 | 0.2873 | ||||||
| La (mmol/L) | EXERCISE_PRE | 1.6 ± 0.5 | 1.4 ± 0.7 | 0.1472 | 1.4 ± 0.4 | 1.4 ± 0.7 | 0.6662 | 0.8854 |
| 1.4512 | 0.4312 | 69.0004 | ||||||
| 0.8152 | 0.1252 | 0.0424 | ||||||
| EXERCISE_POST | 17.7 ± 2.5 | 17.5 ± 2.8 | 0.7992 | 17.0 ± 2.5 | 17.0 ± 1.8 | 0.9861 | 0.7074 | |
| 0.2552 | −0.0181 | 65.0004 | ||||||
| 0.0742 | − 0.0081 | −0.0974 | ||||||
| BE (mmol/L) | EXERCISE_PRE | 2.2 ± 1.0 | 3.6 ± 2.6 | 0.0731 | 2.4 ± 1.5 | 2.6 ± 2.0 | 1.0002 | 0.1664 |
| −1.9811 | 0.0002 | 47.5004 | ||||||
| −0.6831 | 0.0002 | 0.3404 | ||||||
| EXERCISE_POST | −16.9 ± 2.7 | −16.0 ± 2.6 | 0.4531 | −16.2 ± 3.0 | −16.7 ± 2.5 | 0.6581 | 0.4953 | |
| −0.7781 | 0.4551 | 0.6943 | ||||||
| −0.3411 | 0.1581 | 0.2833 |
1Data analyzed by t-test for dependent variables; effect size expressed as Cohen’s d. 2Data analyzed by Wilcoxon signed-rank test; effect size expressed as rank correlation coefficient (r). 3Data analyzed by t-test for independent variables; effect size expressed as Cohen’s d. 4Data analyzed by Mann−Whitney U test; effect size expressed as Glass’s rank-biserial correlation coefficient (r). Abbreviations: BE – base excess, EXERCISE_PRE – value before exercise tests, EXERCISE_POST – value 3-min after the second Wingate anaerobic test, HCO3¯– bicarbonate, La – blood lactate, PLA-PRE – before placebo treatment, PLA-POST – after placebo treatment, SB-PRE – before sodium bicarbonate supplementation, SB-POST – after sodium bicarbonate supplementation
Blood acid-base balance markers – acute supplementation strategy
| BASE | SB | PLA | |||
|---|---|---|---|---|---|
| pH | EXERCISE_PRE | 7.41 ± 0.02 | 7.41 ± 0.03 | 7.41 ± 0.02 | 0.5931 |
| 1.0001 | |||||
| 0.0461 | |||||
| EXERCISE_POST | 7.18 ± 0.04a | 7.24 ± 0.05b | 7.18 ± 0.04a | 0.0002 | |
| 15.5002 | |||||
| 0.6462 | |||||
| HCO3 | EXERCISE_PRE | 25.9 ± 1.0 | 26.1 ± 1.2 | 25.6 ± 0.8 | 0.5582 |
| 1.1672 | |||||
| 0.0492 | |||||
| EXERCISE_POST | 13.3 ± 1.5a | 15.4 ± 1.9b | 13.2 ± 1.6a | 0.0002 | |
| 18.1672 | |||||
| 0.7572 | |||||
| La (mmol/L) | EXERCISE_PRE | 1.3 ± 0.33 | 1.3 ± 0.5 | 1.2 ± 0.5 | 0.8502 |
| 0.3262 | |||||
| 0.0142 | |||||
| EXERCISE_POST | 16.4 ± 2.5b | 17.2 ± 2.2b | 15.2 ± 3.0a | 0.0092 | |
| 9.4562 | |||||
| 0.3942 | |||||
| BE (mmol/L) | EXERCISE_PRE | 2.4 ± 1.1 | 2.1 ± 1.4 | 2.2 ± 1.1 | 0.9202 |
| 0.1672 | |||||
| 0.0072 | |||||
| EXERCISE_POST | −16.1 ± 2.7a | −13.0 ± 3.3b | −16.4 ± 2.9a | 0.0002 | |
| 18.0002 | |||||
| 0.7502 |
1Data analyzed by one-way ANOVA with repeated measurements; effect size expressed as partial eta-squared (); 2Data analyzed by Friedman’s ANOVA and subsequent two-group comparisons by Wilcoxon signed-rank test; effect size expressed as Kendall’s Concordance Coefficient W; ab – different letter inscriptions refer to statistical differences between BASE, PLA and SB. Abbreviations: BASE – baseline (no supplementation), BE – base excess EXERCISE_PRE – value before exercise tests, EXERCISE_POST – value 3 min after the second Wingate anaerobic test, HCO3¯- bicarbonate, La – blood lactate, PLA – after placebo supplementation, SB – after sodium bicarbonate supplementation